DK0716857T3 - Anvendelse af rapamycin til behandling af anæmi - Google Patents

Anvendelse af rapamycin til behandling af anæmi

Info

Publication number
DK0716857T3
DK0716857T3 DK95308503T DK95308503T DK0716857T3 DK 0716857 T3 DK0716857 T3 DK 0716857T3 DK 95308503 T DK95308503 T DK 95308503T DK 95308503 T DK95308503 T DK 95308503T DK 0716857 T3 DK0716857 T3 DK 0716857T3
Authority
DK
Denmark
Prior art keywords
rapamycin
anemia
treatment
mammal
intrabronchially
Prior art date
Application number
DK95308503T
Other languages
Danish (da)
English (en)
Inventor
Jay Joseph Armstrong
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of DK0716857T3 publication Critical patent/DK0716857T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK95308503T 1994-12-13 1995-11-27 Anvendelse af rapamycin til behandling af anæmi DK0716857T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/354,977 US5561138A (en) 1994-12-13 1994-12-13 Method of treating anemia

Publications (1)

Publication Number Publication Date
DK0716857T3 true DK0716857T3 (da) 2002-08-05

Family

ID=23395715

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95308503T DK0716857T3 (da) 1994-12-13 1995-11-27 Anvendelse af rapamycin til behandling af anæmi

Country Status (12)

Country Link
US (1) US5561138A (es)
EP (1) EP0716857B1 (es)
JP (1) JPH08208661A (es)
KR (1) KR100423825B1 (es)
AT (1) ATE215822T1 (es)
CA (1) CA2164921A1 (es)
DE (1) DE69526311T2 (es)
DK (1) DK0716857T3 (es)
ES (1) ES2179862T3 (es)
HK (1) HK1010345A1 (es)
MX (1) MX9505187A (es)
PT (1) PT716857E (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1289815B1 (it) * 1996-12-30 1998-10-16 Sorin Biomedica Cardio Spa Stent per angioplastica e relativo procedimento di produzione
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
DE60136200D1 (de) 2000-09-19 2008-11-27 Wyeth Corp Wasserlösliche rapamycin-ester
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
CN1545512A (zh) 2001-08-22 2004-11-10 惠氏公司 雷帕霉素二醛化合物
ES2246409T3 (es) 2001-08-22 2006-02-16 Wyeth 29-enoles de rapamicina.
KR101131794B1 (ko) * 2002-07-30 2012-03-30 와이어쓰 엘엘씨 Ｃｃｉ-779 공용매 농축액, 비경구 ｃｃｉ-779 제형 및 비경구 ｃｃｉ-779 제형의 제조방법
US20040077677A1 (en) * 2002-09-17 2004-04-22 Wyeth Oral formulations
AR042938A1 (es) * 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
CA2519338A1 (en) * 2003-04-22 2004-11-04 Wyeth Antineoplastic combinations
EP1761540B1 (en) 2004-05-13 2016-09-28 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
EP1755609A1 (en) * 2004-05-25 2007-02-28 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
US8313763B2 (en) * 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
WO2006041942A2 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
CA2629714A1 (en) 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of an mtor inhibitor to treat patients with cancer
US20100081681A1 (en) * 2006-08-16 2010-04-01 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
EP2702993B1 (en) 2006-09-13 2017-12-06 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
CN102231969A (zh) * 2008-10-03 2011-11-02 万能医药公司 大环内酯化合物及其使用方法
CA2743491C (en) 2008-11-11 2016-10-11 Zelton Dave Sharp Inhibition of mammalian target of rapamycin
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CA3092449A1 (en) 2008-11-13 2010-05-20 Gilead Calistoga Llc Therapies for hematologic malignancies
MX2011009955A (es) 2009-03-24 2011-11-18 Gilead Calistoga Llc Atropisomeros de derivados de 2-purinil-3-tolil-quinazolinona y metodos de uso.
CN102612564B (zh) 2009-04-10 2015-08-26 齐海燕 新的抗衰老试剂及其鉴别方法
CN102458410A (zh) 2009-04-20 2012-05-16 吉联亚·卡利斯托加有限责任公司 治疗实体瘤的方法
MX2012000817A (es) 2009-07-21 2012-05-08 Gilead Calistoga Llc Tratamiento para desordenes del higado con inhibidores pi3k.
US9364507B2 (en) 2009-08-11 2016-06-14 Imagilin Technology, Llc Probiotic enhancement of steroid and immune suppressor activity in mammals with chronic diseases
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
AU2013203620B2 (en) 2012-03-05 2015-11-19 Gilead Calistoga Llc Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
WO2014059295A1 (en) 2012-10-12 2014-04-17 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors to treat vascular cognitive impairment
EP2968281B1 (en) 2013-03-13 2020-08-05 The Board of Regents of The University of Texas System Mtor inhibitors for prevention of intestinal polyp growth
JP2017500319A (ja) 2013-12-20 2017-01-05 ギリアード カリストガ エルエルシー （ｓ）−２−（１−（９ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３ｈ）−オンの塩酸塩の多形形態
PL3083630T3 (pl) 2013-12-20 2020-02-28 Gilead Calistoga Llc Sposoby otrzymywania inhibitorów 3-kinazy fosfatydyloinozytolu
ES2900426T3 (es) 2013-12-31 2022-03-16 Rapamycin Holdings Llc Preparaciones orales y uso de nanopartículas de rapamicina
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
NZ726360A (en) 2014-06-13 2018-04-27 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
KR20230010641A (ko) * 2020-05-15 2023-01-19 셀진 코포레이션 ACTRIIB 리간드 트랩 및 mTOR 억제제를 사용한 빈혈 치료 방법 및 조성물
CN116459248B (zh) * 2023-04-27 2024-02-13 中国人民解放军陆军军医大学第二附属医院 雷帕霉素在制备治疗肿瘤相关性贫血的药物中的应用和药物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) * 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
JP2675194B2 (ja) * 1990-08-10 1997-11-12 スミスクライン・ビーチャム・コーポレイション 免疫抑制組成物
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
IL101353A0 (en) * 1991-04-03 1992-11-15 American Home Prod Pharmaceutical compositions for treating diabetes
US5321009A (en) * 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
US5091389A (en) * 1991-04-23 1992-02-25 Merck & Co., Inc. Lipophilic macrolide useful as an immunosuppressant
EP0525960B1 (en) 1991-06-18 1996-03-20 American Home Products Corporation Use of rapamycin for the treatment of adult T-cell leukemia/lymphoma
IL102414A (en) * 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
US5286730A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5286731A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5288711A (en) * 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
GB9302567D0 (en) * 1993-02-10 1993-03-24 Smithkline Beecham Plc Novel compound
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.

Also Published As

Publication number Publication date
PT716857E (pt) 2002-08-30
DE69526311T2 (de) 2002-11-28
HK1010345A1 (en) 1999-06-17
EP0716857B1 (en) 2002-04-10
CA2164921A1 (en) 1996-06-14
KR100423825B1 (ko) 2004-06-26
KR960021019A (ko) 1996-07-18
US5561138A (en) 1996-10-01
DE69526311D1 (de) 2002-05-16
MX9505187A (es) 1997-04-30
JPH08208661A (ja) 1996-08-13
EP0716857A1 (en) 1996-06-19
ATE215822T1 (de) 2002-04-15
ES2179862T3 (es) 2003-02-01

Similar Documents

Publication Publication Date Title
DK0716857T3 (da) Anvendelse af rapamycin til behandling af anæmi
KR930703001A (ko) 전신 홍반성낭창의 치료방법
DK0789567T3 (da) En fremgangsmåde til behandling af vaskulære hovedpiner
LU91271I2 (fr) Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI)
DK0931023T3 (da) Fremgangsmåde til behandling af ammoniakholdigt spildevand
ES2059296T3 (es) Inhibidores de proteasas retrovirales.
HK1063427A1 (en) Anti-ngf antibodies for the treatment of various disorders
HU912359D0 (en) The use of flupirtine active agents for treating muscle-tension
DE59300043D1 (de) Maschine zum Waschen von gefliesten Oberflächen.
DK0456502T3 (da) Apparat til påføring af overfladebehandling.
EA199800764A1 (ru) Способ лечения или предупреждения макулярного отека или возрастной макулярной дистрофии
TR200001290T2 (tr) Estrojen mahrumiyet sendromunu tedavi etmek için yararlı 2-aril-3-aroilbenzo(b) tiofenler.
DK0888330T3 (da) Fremgangsmåder til behandling eller forebyggelse af interstitiel cystitis
DE29906545U1 (de) Maschine zum Feinbearbeiten der Zahnflanken von verzahnten Werkstücken
DK0517787T3 (da) Fremgangsmåde til behandling af terapiresistent skizofreni med amperozide
DK0821955T3 (da) Anvendelse af 3-(4-heoxyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridin (xanomelin) til behandling af bipolar lidelse
MY129918A (en) Method for treating hypertension.
NO972558D0 (no) Sett for osteoporose-behandlingssyklus
BR0210678A (pt) Carbamatos de 2-heterocìclicos-1,2-etanodióis
DE59710787D1 (de) Vorrichtung zum massfinishen von kurbelwellen oder dergleichen werkstücken
ATE236117T1 (de) Radikalabfänger
DK0642574T3 (da) Detergentsammensætninger
FR2716346B3 (fr) Gant de ponçage.
ES1013369Y (es) Maquina elaboradora para el tratamiento de superficies de piezas de trabajo.
EA200001105A1 (ru) 10-камфорсульфонат пароксетина для лечения нарушений цнс